Overview

Safety and Effectiveness of Giving an Anti-HIV Drug Combination of Adefovir Dipivoxil Plus Didanosine Plus Efavirenz Plus Lamivudine Once Daily to HIV-Infected Patients

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to see if it is safe and effective to give HIV-infected patients a new combination of anti-HIV drugs taken once daily.
Phase:
Phase 2
Details
Lead Sponsor:
Gilead Sciences
Collaborators:
Bristol-Myers Squibb
Dupont Applied Biosciences
Glaxo Wellcome
Treatments:
Adefovir
Adefovir dipivoxil
Didanosine
Efavirenz
Lamivudine